Patient may experience adverse events ranging from fever, chills and malaise, to severe adverse events including systemic invasive mycoses or systemic bacterial sepsis.
Material in the patient's bloodstream can result in serious adverse health consequences such as the development of blood clots, embolism of the excess material to vital organs, or death.
L'Agenzia Italiana del Farmaco rende disponibili nuove e importanti informazioni sull'incremento della mortalità osservata in recenti
studi clinici con bendamustina.
Risk of failure of the device to initiate therapy.
There is a reasonable probability that the patient may experience adverse events, ranging from fever, chills and malaise, to severe adverse events including systemic invasive mycoses or systemic bacterial sepsis.
Accuracy errors may lead to patient deaths, serious or life-threatening injuries, and inaccurate, aborted, or prolonged medical procedures Posted 06/15/2017
Failed dissolution could result in less drug being absorbed. Posted 06/15/2017
An extreme and unexpected reduction in dose than expected could lead to a delay in treatment, disruption of clinical care of the patient, and worsening of patient’s conditions. Posted 06/15/2017
A patient may experience adverse events ranging from fever, chills and malaise, to severe adverse events including systemic invasive mycoses or systemic bacterial sepsis. Posted 06/16/2017
The possibility of decreased quality and consistency of the product, may have an impact on the safety and efficacy of the product posing a risk to patients.
80.211.154.110
